A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma

A. M. Evens*, K. R. Carson, J. Kolesar, C. Nabhan, I. Helenowski, N. Islam, B. Jovanovic, P. M. Barr, P. F. Caimi, S. A. Gregory, L. I. Gordon

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Fingerprint Dive into the research topics of 'A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma'. Together they form a unique fingerprint.

Medicine & Life Sciences